Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups.

BACKGROUND Glycemic variability has been proposed as a contributing factor in the development of diabetes complications. Multiple measures exist to calculate the magnitude of glycemic variability, but normative ranges for subjects without diabetes have not been described. For treatment targets and clinical research we present normative ranges for published measures of glycemic variability. METHODS Seventy-eight subjects without diabetes having a fasting plasma glucose of <120 mg/dL (6.7 mmol/L) underwent up to 72 h of continuous glucose monitoring (CGM) with a Medtronic Minimed (Northridge, CA) CGMS(®) Gold device. Glycemic variability was calculated using EasyGV(©) software (available free for non-commercial use at www.easygv.co.uk ), a custom program that calculates the SD, M-value, mean amplitude of glycemic excursions (MAGE), average daily risk ratio (ADRR), Lability Index (LI), J-Index, Low Blood Glucose Index (LBGI), High Blood Glucose Index (HBGI), continuous overlapping net glycemic action (CONGA), mean of daily differences (MODD), Glycemic Risk Assessment in Diabetes Equation (GRADE), and mean absolute glucose (MAG). RESULTS Eight CGM traces were excluded because there were inadequate data. From the remaining 70 traces, normative reference ranges (mean±2 SD) for glycemic variability were calculated: SD, 0-3.0; CONGA, 3.6-5.5; LI, 0.0-4.7; J-Index, 4.7-23.6; LBGI, 0.0-6.9; HBGI, 0.0-7.7; GRADE, 0.0-4.7; MODD, 0.0-3.5; MAGE-CGM, 0.0-2.8; ADDR, 0.0-8.7; M-value, 0.0-12.5; and MAG, 0.5-2.2. CONCLUSIONS We present normative ranges for measures of glycemic variability in adult subjects without diabetes for use in clinical care and academic research.

[1]  D. Matthews,et al.  Time series analysis in endocrinology. , 1988, Acta paediatrica Scandinavica. Supplement.

[2]  Michael Stumvoll,et al.  Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. , 2003, Diabetes.

[3]  W. F. Taylor,et al.  Mean Amplitude of Glycemic Excursions, a Measure of Diabetic Instability , 1970, Diabetes.

[4]  J. Levy,et al.  A method for assessing quality of control from glucose profiles , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[5]  E. Kilpatrick,et al.  Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes , 2007, Diabetologia.

[6]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[7]  C. McDonnell,et al.  A novel approach to continuous glucose analysis utilizing glycemic variation. , 2005, Diabetes technology & therapeutics.

[8]  D. Giugliano,et al.  Intermittent high glucose enhances ICAM‐1, VCAM‐1, E‐selectin and interleukin‐6 expression in human umbilical endothelial cells in culture: the role of poly(ADP‐ribose) polymerase , 2004, Journal of thrombosis and haemostasis : JTH.

[9]  B. Zinman,et al.  Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited , 2008, Diabetes.

[10]  Antonio Ceriello,et al.  Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. , 2003, Diabetes.

[11]  J. Schlichtkrull,et al.  [M-VALUE, AN INDEX FOR BLOOD SUGAR CONTROL IN DIABETICS]. , 1964, Ugeskrift for laeger.

[12]  G. Damante,et al.  Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. , 2001, American journal of physiology. Endocrinology and metabolism.

[13]  Jean-Paul Cristol,et al.  Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. , 2006, JAMA.

[14]  S. Heller,et al.  Continuous glucose monitoring in patients with insulinoma , 2008, Clinical endocrinology.

[15]  W. F. Taylor,et al.  Day-to-day variation of continuously monitored glycaemia: A further measure of diabetic instability , 1972, Diabetologia.

[16]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[17]  Joost B L Hoekstra,et al.  Relationship between interstitial and blood glucose in type 1 diabetes patients: delay and the push-pull phenomenon revisited. , 2007, Diabetes technology & therapeutics.

[18]  J. DeVries,et al.  Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes , 2007, Diabetologia.

[19]  Robert Cuddihy,et al.  Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. , 2008, Diabetes technology & therapeutics.

[20]  Wójcicki Jm,et al.  J"-index. A new proposition of the assessment of current glucose control in diabetic patients. , 1995 .

[21]  Weiqing Wang,et al.  Establishment of normal reference ranges for glycemic variability in Chinese subjects using continuous glucose monitoring , 2011, Medical science monitor : international medical journal of experimental and clinical research.

[22]  J. Hans DeVries,et al.  Glucose variability is associated with intensive care unit mortality* , 2010, Critical care medicine.

[23]  P. Hindmarsh,et al.  Validation of Continuous Glucose Monitoring in Children and Adolescents With Cystic Fibrosis , 2009, Diabetes Care.

[24]  G. Paolisso,et al.  Bariatric Surgery Reduces Oxidative Stress by Blunting 24-h Acute Glucose Fluctuations in Type 2 Diabetic Obese Patients , 2009, Diabetes Care.

[25]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[26]  Michael Brownlee,et al.  The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes , 2007, Diabetes Care.

[27]  D. Goldstein,et al.  Glycated hemoglobin: methodologies and clinical applications. , 1986, Clinical chemistry.

[28]  Daniel J Cox,et al.  Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. , 2003, Diabetes technology & therapeutics.

[29]  A. Shapiro,et al.  Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. , 2004, Diabetes.

[30]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.